Four Novel Agents for Treatment of Duchenne Muscular Dystrophy，include GlaxoSmithKline/Prosensa’s GSK-2402968/PRO-051/drisapersen, Santhera/Takeda’s Catena/Sovirma’s idebenone, AVI BioPharma’s eteplirsen/AVI-4658 and Prosensa’s PRO-044.
“Glucocorticoid treatment is a common offered therapy for that treatment of DMD,” said choice Resources Analyst Richa Mukherjee, M.Sc., M.Phil., Ph.D. “It’s a symptomatic therapy that will not aim for the result in of the illness and its use is often accompanied by concerning part effects. The deficiency of your disease-modifying therapy to treat DMD presents a higher unmet have to have for medicine developers.”
According to Niche Markets and Rare Diseases: Muscular Dystrophy, choice Resources forecasts the launch of four new agents to treat DMD by 2021. These therapies consist of GlaxoSmithKline/Prosensa’s GSK-2402968/PRO-051/drisapersen, Santhera/Takeda’s Catena/Sovirma’s idebenone, AVI BioPharma’s eteplirsen/AVI-4658 and Prosensa’s PRO-044. of those therapies, GSK-2402968, eteplirsen and PRO-044 are disease-modifying therapies that will seriously saturate their aim for individual segments however, given the tiny dimension of those segments, the marketplace will nevertheless be quite receptive to novel disease-modifying agents.
“The DMD marketplace will grow being a result of polytherapy as patients will probably be taken care of with mutation-specific disease-modifying drug treatments in inclusion to symptomatic treatments like idebenone,” said Dr. Mukherjee.
“Symptomatic therapies will continue to perform a main position for any the vast majority of DMD patients since the new disease-modifying agents aim for only a subset of the DMD individual population.”